Advances in Combination of Antiangiogenic Agents Targeting VEGF-binding and Conventional Chemotherapy and Radiation for Cancer Treatment

Journal of the Chinese Medical Association

Volumn 73, Issue 6, 2010, Pages 281-288

  Teng, Li Song ^a   Jin, Ke Tao ^a,b   He, Kui Feng ^a   Wang, Hao Hao ^a   Cao, Jiang ^c   Yu, De Cao ^d  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Zhuji Hospital   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d Chengdu Kanghong Biotechnology Co Ltd   (China)

Author keywords

Antiangiogenic agents; Bevacizumab; VEGF targeted agents; VEGF Trap

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; KH 902; KH 903; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLACEBO; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; VASCULOTROPIN A;

BLEEDING; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOMYOPATHY; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG SAFETY; DYSPNEA; EPISTAXIS; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; LACRIMATION; LEUKOPENIA; LEWIS CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; NEOPLASM; NEUROPATHY; NEUTROPENIA; OVARY CANCER; OVARY CARCINOMA; PERICARDIAL EFFUSION; PROTEINURIA; RADIATION DOSE; RECTUM CANCER; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOSIS; VOMITING; ANTAGONISTS AND INHIBITORS; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASMS; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77954254816     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/S1726-4901(10)70062-9     Document Type: Review

References (58)

1. Shibuya M Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001, 26:25-35.
2. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy?. Nature Rev Cancer 2002, 2:826-835.
3. Folkman J Fundamental concepts of the angiogenic process. Curr Mol Med 2003, 3:643-651.
4. Hicklin DJ, Ellis LM Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
5. Ferrara N, Gerber HP, LeCouter J The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
6. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
7. Giaccone G The potential of antiangiogenic therapy in non-small cell lung cancer. Clin Cancer Res 2007, 13:1961-1970.
8. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
9. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145-147.
10. Ferrara N VEGF as a therapeutic target in cancer. Oncology 2005, 69(Suppl):11-16.
11. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002, 99:11393-11398.
12. Gerber HP, Ferrara N Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cyto-toxic therapy in preclinical studies. Cancer Res 2005, 65:671-680.
13. Wang Y, Fei D, Vanderlaan M, Song A Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004, 7:335-345.
14. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
15. Rowe DH, Huang J, Kayton ML, Thompson R, Troxel A, O'Toole KM, Yamashiro D, et al. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg 2000, 35:30-32.
16. Wulff C, Wilson H, Wiegand SJ, Rudge JS, Fraser HM Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology 2002, 143:2797-2807.
17. Fukasawa M, Korc M Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res 2004, 10:3327-3332.
18. Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, New T, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003, 100:7785-7790.
19. Zhang M, Zhang J, Yan M, Li H, Yang C, Yu D Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choroidal neovascularization in monkeys. Mol Vis 2008, 14:37-49.
20. Zhang M, Yu D, Yang C, Xia Q, Li W, Liu B, Li H The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 2009, 26:204-210.
21. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006, 116:2610-2621.
22. Aita M, Fasola G, Defferrari C, Brianti A, Bello MG, Follador A, Sinaccio G, et al. Targeting the VEGF pathway: antiangio-genic strategies in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 2008, 68:183-196.
23. Jain RK, Duda DG, Clark JW, Loeffler JS Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006, 3:24-40.
24. Kerbel RS Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 2006, 312:1171-1175.
25. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999, 59:3374-3378.
26. Gupta VK, Jaskowiak NT, Beckett MA, Mauceri HJ, Grunstein J, Johnson RS, Calvin DA, et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 2002, 8:47-54.
27. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under nor-moxic or hypoxic conditions. Cancer Res 2000, 60:5565-5570.
28. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007, 13:3395-3402.
29. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008, 71:1372-1380.
30. Czito BG, Bendell JC, Willett CG, Morse MA, Blobe GC, Tyler DS, Thomas J, et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results. Int J Radiat Oncol Biol Phys 2007, 68:472-478.
31. Ou G, Itasaka S, Zeng L, Shibuya K, Yi J, Harada H, Hiraoka M Usefulness of HIF-1 imaging for determining optimal timing of combining bevacizumab and radiotherapy. Int J Radiat Oncol Biol Phys 2009, 75:463-467.
32. Wachsberger PR, Burd R, Cardi C, Thakur M, Daskalakis C, Holash J, Yancopoulos GD, et al. VEGF trap in combination with radiotherapy improves tumor control in U87 glioblas-toma. Int J Radiat Oncol Biol Phys 2007, 67:1526-1537.
33. Borgström P, Gold DP, Hillan KJ, Ferrara N Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999, 19:4203-4214.
34. Soffer SZ, Moore JT, Kim E, Huang J, Yokoi A, Manley C, O'Toole K, et al. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J Pediatr Surg 2001, 36:1177-1181.
35. Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI, Agus DB Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 2002, 8:3226-3231.
36. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002, 161:1917-1924.
37. Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, de Bruijn EA, et al. Effect of antivascular endothe-lial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003, 88:1979-1986.
38. Wild R, Dings RP, Subramanian I, Ramakrishnan S Carboplatin selectively induces the VEGF stress response in endothelial cells: potentiation of antitumor activity by combination treatment with antibody to VEGF. Int J Cancer 2004, 110:343-351.
39. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xeno-grafts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007, 13:3942-3950.
40. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 2003, 79:391-397.
41. Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M, Allen J, et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 2006, 12:3124-3129.
42. Chan D, Allen H, Hu E, Reese D, Patel G, Gottlieb C, Wax A, et al. Phase II study of docetaxel (D) plus bevacizumab (B) in Her/2 negative metastatic breast carcinoma (MBC). J Clin Oncol 2006, 24:605s. (abstract 13047). 2006 ASCO Annual Meeting Proceedings Part I.
43. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23:792-799.
44. Miller KD, Wang M, Gralow J, Dickler M, Cobleigh MA, Perez EA, Shenkier TN, et al. A randomized phase III trial of pacli-taxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res 2005, 94(Suppl):S6. (abstract 3).
45. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60-65.
46. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, et al. Addition of bevacizumab to bolus flu-orouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23:3697-3705.
47. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
48. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
49. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005, 23:8033-8040.
50. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
51. Cassidy J, Clarke S, Rubio E Diaz First efficacy and safety results from XELOX-1/NO16966, a randomised 2 × 2 factorial phase III trial of XELOX vs FOLFOX4 plus bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Ann Oncol 2006, 17(Suppl):LBA3. [Abstract].
52. Saltz LB, Clarke S, Diaz-Rubio W, Scheithauer A, Figer A, Wong R, Koski S, et al. Bevacizumab in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Gastrointestinal Cancers Symposium 2007, abstract 238.
53. Hochster HS, Hart LL, Ramanathan RK, Hainsworth JD, Hedrick EE, Childs BH Safety and efficacy of oxaliplatin/flu-oropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. Proc Am Soc Clin Oncol 2006, abstract 3510.
54. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005, 11:6966-6971.
55. Haroon ZA, Amin K, Saito W, Wilson W, Greenberg CS, Dewhirst MW SU5416 delays wound healing through inhibition of TGF-beta 1 activation. Cancer Biol Ther 2002, 1:121-126.
56. Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, Elfring GL, et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 2001, 6:81-91.
57. Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 2006, 47:887-893.
58. Jain RK Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989.